These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 32832493)

  • 1. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma.
    Lin J; Yang X; Long J; Zhao S; Mao J; Wang D; Bai Y; Bian J; Zhang L; Yang X; Wang A; Xie F; Shi W; Yang H; Pan J; Hu K; Guan M; Zhao L; Huo L; Mao Y; Sang X; Wang K; Zhao H
    Hepatobiliary Surg Nutr; 2020 Aug; 9(4):414-424. PubMed ID: 32832493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
    Jiang Q; Huang J; Zhang B; Li X; Chen X; Cui B; Li S; Guo G
    Front Immunol; 2022; 13():801909. PubMed ID: 35309350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
    Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
    Front Immunol; 2022; 13():946861. PubMed ID: 35967452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancer.
    Wang Y; Xun Z; Yang X; Wang Y; Wang S; Xue J; Zhang N; Yang X; Lu Z; Zhou J; Zhou K; Sang X; Zhao H
    Am J Cancer Res; 2023; 13(3):1026-1037. PubMed ID: 37034211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study.
    Wang Y; Yang X; Wang Y; Xue J; Zhang N; Yang X; Cong N; Zhang J; Zhu C; Zhang L; Hou X; Zhao H
    Cancer Immunol Immunother; 2023 Jul; 72(7):2197-2204. PubMed ID: 36856834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of anti-PD-1 monotherapy
    Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
    Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer.
    Zhu C; Xue J; Wang Y; Wang S; Zhang N; Wang Y; Zhang L; Yang X; Long J; Yang X; Sang X; Zhao H
    Front Immunol; 2023; 14():1109292. PubMed ID: 36742297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
    Zhu C; Li H; Yang X; Wang S; Wang Y; Zhang N; Wang Y; Xue J; Zhang L; Ning C; Yang X; Xun Z; Chao J; Long J; Sang X; Zhu Z; Zhao H
    Cancer Immunol Immunother; 2023 Sep; 72(9):2949-2960. PubMed ID: 37247023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective cohort study on the efficacy and safety for combination therapy of immunotherapy, targeted agent, and chemotherapy versus immunochemotherapy or chemotherapy alone in the first-line treatment of advanced biliary tract carcinoma.
    Zeng J; Ma J; Zeng Z; Yang L; Jiang Y; Mo N; Ma F; Liu C; Li R; Tang J; Qin S; Jiang H
    J Gastrointest Oncol; 2023 Apr; 14(2):758-767. PubMed ID: 37201053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review.
    Mo DC; Luo PH; Huang SX; Wang HL; Huang JF
    Int Immunopharmacol; 2021 Feb; 91():107281. PubMed ID: 33338862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study.
    Zhang Q; Liu X; Wei S; Zhang L; Tian Y; Gao Z; Jin M; Yan S
    Front Oncol; 2021; 11():751391. PubMed ID: 34900698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
    Xia D; Bai W; Wang E; Li J; Chen X; Wang Z; Huang M; Huang M; Sun J; Yang W; Lin Z; Wu J; Li Z; Yang S; Zhu X; Chen Z; Zhang Y; Fan W; Mai Q; Ding R; Nie C; Feng L; Li X; Huang W; Sun J; Wang Q; Lv Y; Li X; Luo B; Wang Z; Yuan J; Guo W; Li K; Li B; Li R; Yin Z; Xia J; Han G
    Liver Cancer; 2022 Jul; 11(4):368-382. PubMed ID: 35978600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study.
    Grünwald V; Powles T; Kopyltsov E; Kozlov V; Alonso-Gordoa T; Eto M; Hutson T; Motzer R; Winquist E; Maroto P; Keam B; Procopio G; Wong S; Melichar B; Rolland F; Oya M; Rodriguez-Lopez K; Saito K; McKenzie J; Porta C
    Eur Urol Oncol; 2023 Aug; 6(4):437-446. PubMed ID: 36720658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma.
    Wu CJ; Lee PC; Hung YW; Lee CJ; Chi CT; Lee IC; Hou MC; Huang YH
    Cancer Immunol Immunother; 2022 Nov; 71(11):2631-2643. PubMed ID: 35347395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC.
    Wang Y; Zhang N; Xue J; Zhu C; Wang Y; Zhang L; Yang X; Wang H; Wang S; Chao J; Yang X; Zhao H
    Front Immunol; 2023; 14():1084843. PubMed ID: 36733485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results.
    Ueno M; Ikeda M; Sasaki T; Nagashima F; Mizuno N; Shimizu S; Ikezawa H; Hayata N; Nakajima R; Morizane C
    BMC Cancer; 2020 Nov; 20(1):1105. PubMed ID: 33198671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
    Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ
    Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
    Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
    J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
    Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
    J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.